MARKET WIRETradingView • 1d ago
ENDRA Life Sciences Inc. Estimates – NASDAQ:NDRATradingView report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
Why NDRA Stock advanced +1.05% Today — RQD Quant Desk Flash
$4.80 +1.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.80
ENDRA Life Sciences Inc. (NDRA) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $7.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NDRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, ENDRA Life Sciences Inc. (NASDAQ: NDRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.80 (+1.05% 1D, market cap $7.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NDRA ranks #581 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NDRA compare to IRIX and ITOC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NDRA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRIX (IRIDEX Corporation) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M) and ITOC (iTonic Holdings Ltd (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $19.0M). Among the 5-stock peer group, NDRA leads on earnings multiple (N/A) while NDRA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NDRA?
▼
Per NDRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681682), ENDRA Life Sciences Inc. generated $16.1M in revenue (-46.7% YoY), -$7.0M in net income, and -$5.2M in free cash flow against $3.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.80 (+0.00%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NDRA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY NDRA SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)
FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 42.7 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$5.04-11.3% Next Q
44
Q2 (-2Q)Grade D$4.47+11% Next Q
41
Q3 (-1Q)Grade E$4.96-3.2% Next Q
39
CurrentGrade D-$4.80-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NDRA Turnaround Squeeze
While NDRA currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.45) and Max Pain ($5.04) forces dealer call-delta covering toward $7.30.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NDRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NDRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NDRA Stock advanced +1.05% Today — RQD Quant Desk Flash
ENDRA Life Sciences Inc. (NDRA) advanced +1.05% to $4.80, trading at 46% of its 52-week range ($2.96 – $6.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 46% of its 52-week range ($2.96 – $6.95) with RSI-14 at 42.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.80 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NDRA Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 1d ago
Daré Bioscience, Inc. (DARE) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance UK • 1d ago
Daré Bioscience, Inc. (DARE) stock price, news, quote and historyYahoo Finance UK report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingKey • 1d ago
Top U.S. Stock Gainers: Biggest Price IncreasesTradingKey report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 2d ago
ProPhase Labs, Inc. (PRPH) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
52-Week Low U.S. Stocks & New Market LowsTradingKey report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Australia • 2d ago
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and historyYahoo Finance Australia report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key DataTradingKey report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NDRA)
- ✓Walkthrough of NDRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NDRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.83%📐 HORIZONTAL RANGE
2026-11-03O $4.88H $4.88L $4.75C $4.80VOL 10.6K
RES: $6.82SUP: $4.30SMA50: $5.45SMA200: $4.81
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NDRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -46.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NDRA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NDRA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NDRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NDRA)
Health Care Rank #581 of 1015
⚔️ IRIX vs NDRA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NDRA vs. IRIX, ITOC, NUWE, NXL)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, ENDRA Life Sciences Inc. (NDRA) ranks #581 by composite RQD confidence (36/100, grade D-) and #918 by equity capitalization ($7.1M). Within this direct 5-issuer industry benchmark cohort, NDRA leads on earnings valuation at N/A trailing P/E, while NDRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NDRA currently leads its immediate peer cohort in composite quantitative strength at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NDRA
ACTIVE
ENDRA Life Sciences Inc. | D- | 36/100 | — | — | -35.0% | +1.05% | $7.1M | Benchmark Subject |
| IRIX IRIDEX Corporation | E | 27/100 | — | 36.5% | -35.0% | +1.33% | $12.5M | /irix-vs-ndra → |
| ITOC iTonic Holdings Ltd (Class A) | E | 33/100 | — | 62.6% | -35.0% | -9.61% | $19.0M | /itoc-vs-ndra → |
| NUWE Nuwellis Inc. | E | 33/100 | — | 62.0% | -35.0% | -8.80% | $2.3M | /nuwe-vs-ndra → |
| NXL Nexalin Technology Inc. | E | 32/100 | — | 79.7% | -35.0% | -5.94% | $1.8M | /nxl-vs-ndra → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001681682 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), ENDRA Life Sciences Inc. (NDRA) reported GAAP revenue of $16.1M (-46.7% vs. FY2024 revenue of $30.3M , and -45.2% cumulative change since FY2023) , GAAP net income of -$7.0M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+29.9% YoY). On the balance sheet, NDRA closed FY2025 with $3.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $16.1M | -$7.0M | -$5.2M | -$5.2M | $3.9M | — |
| FY2024 (FY) | 2024-12-31 | $30.3M | -$11.5M | -$7.4M | -$7.4M | $4.5M | — |
| FY2023 (FY) | 2023-12-31 | $29.5M | -$10.1M | -$9.5M | -$9.5M | — | — |
3. NDRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, ENDRA Life Sciences Inc. (NASDAQ: NDRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.80 (+1.05% 1D, market cap $7.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NDRA ranks #581 in composite RQD confidence.
How does NDRA compare to IRIX and ITOC in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NDRA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRIX (IRIDEX Corporation) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M) and ITOC (iTonic Holdings Ltd (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $19.0M). Among the 5-stock peer group, NDRA leads on earnings multiple (N/A) while NDRA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NDRA?
Per NDRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681682), ENDRA Life Sciences Inc. generated $16.1M in revenue (-46.7% YoY), -$7.0M in net income, and -$5.2M in free cash flow against $3.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NDRA trading relative to its 50-day, 200-day, and 52-week technical levels?
NDRA last traded at $4.80 (+1.05% on volume of 5,797 shares), positioning the stock -11.93% below its 50-day simple moving average ($5.45) and -0.21% below its 200-day simple moving average ($4.81). Across its 52-week range of $2.96 to $6.95, NDRA sits at the 46.1% percentile with a 14-day RSI of 42.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.20 to $5.40).
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ SEC XBRL & RQD VERIFIED
NDRA — ENDRA Life Sciences Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
ENDRA Life Sciences Inc. (NDRA) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.80 (+1.05% 1D, market capitalization $7.1M).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
ENDRA Life Sciences Inc. (NDRA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. It carries a market capitalization of $0.0B, which is inconsistent with the $7.3M figure in market data and should be treated with caution. — describes its specific products, customers, or revenue model. Reported revenue is — in each listed period.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ENDRA Life Sciences Inc. (NDRA) reported $16.1M in annual revenue (up from $30.3M in FY2024, -46.7% YoY) and -$7.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($29.5M revenue, -$10.1M net income) through FY2025, NDRA scaled operating cash flow to -$5.2M and free cash flow to -$5.2M, backed by $3.9M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.96 – $6.95 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
A prospective investor should note that the absence of mapped links means this dossier cannot identify which suppliers, customers, or sector peers would transmit shocks to NDRA.
- Key Question #1: Can NDRA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $16.1M and free cash flow of -$5.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is NDRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NDRA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for ENDRA Life Sciences Inc. (NDRA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 1d ago
ENDRA Life Sciences Inc. Estimates – NASDAQ:NDRA TradingView report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Daré Bioscience, Inc. (DARE) Stock Price, News, Quote & History Yahoo! Finance Canada report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
Daré Bioscience, Inc. (DARE) stock price, news, quote and history Yahoo Finance UK report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingKey • 1d ago
Top U.S. Stock Gainers: Biggest Price Increases TradingKey report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago
ProPhase Labs, Inc. (PRPH) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
52-Week Low U.S. Stocks & New Market Lows TradingKey report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Australia • 2d ago
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history Yahoo Finance Australia report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key Data TradingKey report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NDRA Bull vs. Bear Conversation Board — What's Your Call at $4.80?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NDRA 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $5.89 (+24.0%)
📌 Pinned Debate The stock trades at $4.88 with a 52-week range of $2.96 - $6.95 and a 2.95% daily gain, with a GREEN-flagged catalyst item in the news
Here is why I am bullish on NDRA here at $4.75: The stock trades at $4.88 with a 52-week range of $2.96 - $6.95 and a 2.95% daily gain, with a GREEN-flagged catalyst item in the news feed.. Compare NDRA's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Electromedical & Electrotherapeutic Apparatus. As long as cash conversion holds up, dips toward $4.51 are getting bought.
VolSurface_Trader 🐂 BULL
@FadeTheHype Shorting a 5/20 institutional whale-flow stock at $4.75 is dangerous when funds are rotating into Health Care.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $3.75 (-21.1%)
Spot @ $4.75 The company reports zero revenue, negative FCF in every period, ROIC of -35%, and cash falling from $3.2M to $0.8M, with an RQD score o
The company reports zero revenue, negative FCF in every period, ROIC of -35%, and cash falling from $3.2M to $0.8M, with an RQD score of 42.. Look at the math on NDRA: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Electromedical & Electrotherapeutic Apparatus demand softens. I'd wait for a retest of $4.18 before getting long.